Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
237.31
-0.79 (-0.33%)
Official Closing Price
Updated: 7:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Glaukos Announces Participation in Upcoming Investor Conferences
November 03, 2026
From
Glaukos Corporation
Via
Business Wire
US Stock Market Movers: Top Gainers and Losers for the Session
↗
October 29, 2026
Via
Chartmill
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
↗
October 29, 2026
Glaukos’ two newer launches are carrying the company, and its 2027 target may be too low. Here’s what to watch.
Via
The Motley Fool
Top US Stock Gainers and Losers for Oct. 29, 2026
↗
October 29, 2026
Via
Chartmill
Glaukos (NYSE:GKOS): High Growth Momentum Meets a Breakout Setup
↗
October 17, 2026
Via
Chartmill
Glaukos (NYSE:GKOS) Passes Minervini Trend Template and High-Growth Momentum Screen
↗
September 01, 2026
Via
Chartmill
GKOS (Glaukos Corp) Shows Strong Trend Template Compliance and High Growth Momentum on ChartMill
↗
June 20, 2026
Via
Chartmill
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Session
↗
October 29, 2026
Via
Chartmill
Premarket Gainers and Losers on Oct. 29, 2026
↗
October 29, 2026
Via
Chartmill
Glaukos (GKOS) Q3 2026 Earnings Call Transcript
↗
October 28, 2026
Record sales and margin expansion driven by iDose TR and Epioxa launches.
Via
The Motley Fool
Topics
Earnings
Glaukos Q3 Earnings Call Highlights
↗
October 28, 2026
Glaukos (NYSE:GKOS) reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma...
Via
MarketBeat
Topics
Earnings
After-Hours Movers: LABT, NCPL Top Gainers; Fortinet, AUROW Top Losers
↗
October 28, 2026
Via
Chartmill
Glaukos Announces Third Quarter 2026 Financial Results
October 28, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
October 09, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
October 08, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
October 07, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
October 07, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
September 23, 2026
From
Glaukos Corporation
Via
Business Wire
If You Invested $1000 In Glaukos Stock 10 Years Ago, You Would Have This Much Today
↗
September 10, 2026
Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.45%. Currently, Glaukos has a market capitalization of...
Via
Benzinga
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
↗
August 25, 2026
Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%. Currently, Glaukos has a market capitalization of...
Via
Benzinga
Glaukos Announces Participation in Wells Fargo Healthcare Conference
August 19, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos (GKOS) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
iDose TR drove $74M in Q2 revenue as Glaukos raised full-year guidance.
Via
The Motley Fool
Topics
Earnings
Glaukos Q2 Earnings Call Highlights
↗
July 30, 2026
Glaukos (NYSE:GKOS) reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth...
Via
MarketBeat
Topics
Earnings
Glaukos Announces Second Quarter 2026 Financial Results
July 29, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
July 27, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?
↗
July 14, 2026
Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million.
Via
The Motley Fool
Topics
Regulatory Compliance
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?
↗
July 08, 2026
Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.
Via
The Motley Fool
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
July 08, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
June 25, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
May 12, 2026
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit